Amgen Inc (NASDAQ:AMGN)
| 228.95 Delayed Data As of Oct 21 |  -2.13 / -0.92%Today’s Change | 177.05 Today|||52-Week Range 264.97 | -5.03% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $138.1B |
Company Description
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Contact Information
Amgen, Inc. One Amgen Center Drive Thousand Oaks California 91320-1799 |
Employees
Shareholders
| Mutual fund holders | 46.33% |
| Other institutional | 31.67% |
| Individual stakeholders | 0.95% |
Top Executives
| Robert A. Bradway | Chairman, President & Chief Executive Officer |
| Esteban Santos | Executive Vice President-Operations |
| Peter H. Griffith | Chief Financial Officer |
| Mike Zahigian | Chief Information Officer & Senior Vice President |
| David M. Reese | Executive Vice President-Research & Development |
